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Bacillus clausii is a gram-positive rod used as a probiotic to treat diarrhea and the side 
effects of antibiotics such as pseudomembranous colitis. We report a case of B. clausii 
bacteremia in a non-immunocompromised patient with active peptic ulcer disease and acute 
diarrhea. The probiotic was administered during the patient´s hospitalization due to diarrhea 
of infectious origin. B. clausii was identified in the bloodstream of the patient through Matrix-
Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) days after her discharge. 
Given the wide use of probiotics, we alert clinicians to consider this microorganism 
as a causative agent when signs of systemic infection, metabolic compromise, and 
hemodynamic instability establish after its administration and no pathogens have been 
identified that could explain the clinical course.
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Bacteriemia tras la administración de Bacillus clausii para el tratamiento de la diarrea 
aguda: reporte de un caso
Bacillus clausii es un bacilo Gram positivo usado como probiótico para tratar la diarrea y 
efectos adversos de los antibióticos, como la colitis pseudomembranosa. Se reporta un 
caso de bacteriemia por B. clausii en una paciente inmunocompetente con enfermedad 
ulcerosa péptica activa y diarrea aguda. El probiótico le fue administrado durante la 
hospitalización debido al origen infeccioso de la diarrea. B. clausii se identificó en el 
torrente sanguíneo de la paciente, utilizando espectrometría de desorción/ionización 
mediante láser asistido por matriz (Matrix-Assisted Laser Desorption/Ionization, MALDI), 
acoplada a un detector de iones (Time of Flight, TOF) (MALDI-TOF), días después de 
haber sido dada de alta. 
Dado el amplio uso de los probióticos, alertamos a los clínicos para que consideren este 
microorganismo como agente causal cuando se detecten signos de infección sistémica, 
compromiso metabólico, e inestabilidad hemodinámica tras su administración, y no se haya 
identificado ningún patógeno que pueda explicar el cuadro clínico.
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Bacillus clausii is a gram-positive, spore-forming rod, widely used as a 
probiotic (1). Probiotics have been used for hundreds of years to treat different 
diseases. Since the 1960s they have been used to treat viral diarrhea in children 
and the side effects of antibiotic administration (2). Antibiotic-associated side 
effects and Clostridioides difficile diarrhea are well-known scenarios where 
probiotics are proven to be efficient (3). Recent studies on the safety of B. clausii 
administration have concluded that it has intrinsic resistance mechanisms to 
some antibiotics (e.g. macrolides), but no toxin-producing genes or transferrable 
antimicrobial resistance, which makes it very safe (4,5). However, other studies 
have shown no related side effects linked to its use (6-8), and, on the other hand, 
side effects have been inconsistently reported and not adequately assessed. 
Anyway the World Health Organization has acknowledged probiotics might be 
responsible for systemic infections and deleterious metabolic activity (9).
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Case report
An 87-year-old woman arrived at the emergency room of a third-level 
hospital in Colombia reporting 12 days of watery, abundant, fetid diarrhea 
accompanied by brown-colored vomit and melena. She was referred from a 
first-level hospital with several laboratory tests completed. After admission, 
critical care clinicians evaluated the patient and admitted her to the 
intermediate care unit. Her medical history included arterial hypertension, 
chronic obstructive lung disease (COPD), and a cholecystectomy.
The patient appeared somnolent throughout the initial physical evaluation. 
She also had elevated systolic blood pressure (150/80 mm Hg) and tachypnea 
(22 breaths per minute), she had no fever (36,1°C), her pulse was 80 beats 
per minute, her oxygen saturation 97%, the Glasgow Coma Scale score was 
13/15, she had dried oral mucosa and rales in both of her pulmonary fields. 
The examination was otherwise normal.
The previous laboratory findings and those during the patient´s admission 
are summarized in table 1. We initially administered ampicillin/sulbactam (1.5 
grams every six hours) as Klebsiella pneumoniae was documented in a urine 
culture brought by the patient (taken five days before admission) and bacterial 
diarrhea was suspected. There was no previous or recent documentation of 
any urinary symptoms and, therefore, asymptomatic bacteriuria was suspected. 
Two days later, an upper gastrointestinal endoscopy was done. It showed 
three Forrest Class III gastric ulcers for which proton pump inhibitors were 
administered. Sodium, potassium, and water deficits were in constant 
reposition. The patient did not present new episodes of melena or vomit, only 
occasional diarrheic depositions during her stay at the intermediate care unit. 
Based on her clinical evolution, the patient was then transferred to the 
internal medicine unit ten days after admission. She appeared disorientated, 
but no additional signs or symptoms were present, aside from diarrheic 
depositions. An astringent diet was started but abdominal pain and 
diarrhea persisted. The internal medicine physician decided to prescribe an 
Enterogermina™ probiotic (2 billion/5 ml B. clausii spore suspension, strains: 
SIN, O/C, T, and N/R) every six hours as of the 16th day of her hospital stance. 
On day 19, we interviewed the patient again in search of urinary symptoms 
and she reported having dysuria and abdominal pain, which she associated 
with a previous bladder catheterization. At this point, urine analysis, Gram 
stain, culture, and antimicrobial susceptibility testing were done. The urine 
analysis revealed positive leukocyte esterase, pyuria, and bacteriuria. The 















Blood urea nitrogen (mg/dl)
Thromboplastin partial time (s)
Prothrombin time (s)
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           2.2
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         98
    8,080
    6,230 
         14.3
240,000 
         76
           2
       122
       105 
           0.3
           9
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Gram stain identified a Gram-negative rod characterized three days later 
in the urine culture as Escherichia coli with an inhibitor-resistance TEM 
(IRT) pattern as shown by evidence of resistance to ampicillin (MIC ≥32 µg/
ml), ampicillin/sulbactam (MIC ≥32 µg/ml), and preserved sensibility to all 
cephalosporins. We established a diagnosis of probable urinary tract infection 
(UTI) and, given that the antimicrobial susceptibility testing results were only 
available 3 days later, we started the empirical administration of cephalothin 
(1 g/6 h) pending results.
On the 20th day of the hospital stay, the patient began shivering, sweating, 
and did not appear well. Her heart rate was 137 beats per minute, her 
respiratory rate was 30 breaths per minute, her temperature was 38.7 °C, 
her blood pressure was 89/48 mm Hg, and her oxygen saturation was 88% 
without oxygen support. There were signs of phlebitis on the right upper 
limb where the peripheral catheter was placed. The blood analysis showed 
a white blood cell count of 9,020/mm3 [4,500–10,000], neutrophilia of 89%, 
hemoglobin of 9.8 g/dl [12-15.5], and C-reactive protein of 6.3 mg/dl [0–5] 
(table 2). A pair of anaerobic and aerobic blood cultures were drawn from 
peripheral intravenous access. Cephalothin was suspended and intravenous 
vancomycin (1 g/12 h) and cefepime (1 g/12 h) were started to target 
microorganisms responsible for sepsis in the context of a Gram-negative 
rod UTI and Gram-positive cocci phlebitis. Supplementary oxygen was 
administered by nasal cannula due to low oxygen arterial pressure. Figure 1 
summarizes the clinical course after the administration of Enterogermina™.
Table 2. Laboratory and microbiology test results on the 20th day of hospital stance
20th day of 
hospital stance
26th day of 
hospital stance
Reference values
White blood cells (cell/ml)
Neutrophils (cell/µl)
Hemoglobin (g/dl)
Mean corpuscular volume (fl)
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Gastrointestinal Film Array Panel™ (22nd day)
Enteroaggregative and Enteropathogenic E. coli 
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One day later, the patient’s vital signs were back to normal. She tolerated 
oral intake, but still had diarrhea. Periodically, we assessed the renal function 
in creatinine and blood urea nitrogen (BUN) samples, which were never out 
of range.  However, abdominal pain and diarrhea persisted. On day 22, we 
did coprology, stool culture, gastrointestinal FilmArray™, colonoscopy, and 
abdominal ultrasonography in search of the infectious source of diarrhea. 
Four days later, the FilmArray™ was positive for enteroaggregative and 
enteropathogenic E. coli (Protocol: Stool FA v2.3, Pouch: GI Panel v2.1). The 
other microbiological tests and diagnostic images were normal. By the 26th 
day, a new complete blood cell count was within normal range, except for the 
persistence of mild anemia.
The results from the blood culture Gram stain were available on day 
22 (figure 2), upon which we added intravenous ampicillin (2 g/4 h) to the 
previous antimicrobial therapy to target the Gram-positive rods identified. 
An infectious disease specialist assessed the therapy and decided to start 
intravenous gentamicin (5 m/kg in two doses per day for 7 days), continue the 
recently added ampicillin, and suspend the empiric therapy with vancomycin 
and cefepime. The patient´s clinical course improved and her vital signs were 
within normal range. The last episode of diarrhea was on the 27th day. The 
7-day antimicrobial treatment was completed and supplementary oxygen was 
gradually removed. The patient was discharged on the 33rd day with complete 
clinical recovery.
Figure 1. Summary of bacteremia course
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As the typification of the Gram-positive rod identified in the blood culture 
Gram stain was not possible, we resorted to MALDI-TOF spectrometry whose 
results were available 2 days after the patient was discharged reporting the 
presence of B. clausii (figure 2).
Discussion
We reported the case of an 87-year-old female patient with upper 
gastrointestinal bleeding, diarrhea of infectious origin, and recent use of proton 
pump inhibitors in whom probiotics containing B. clausii were administered 
and later identified as the cause of bacteremia and hemodynamic instability. 
We discuss here previously published case reports of bacteremia due to B. 
clausii administration, recommended scenarios to administer probiotics, and 
the potential risk factors/clinical profiles that could make a patient susceptible 
to bacteremia caused by probiotics containing Bacillus spp. 
The systemic infections, especially Bacillus spp. bacteremia, are rare 
conditions and, frequently, they are considered contaminant bacteria in blood 
cultures. The most common agent of Bacillus spp. bacteremia is Bacillus 
cereus but there are reports of bacteremia by probiotics containing Bacillus 
subtilis and B. clausii like the case we are now reporting (10,11).
Recently, three cases of immunocompromised patients who developed 
clinically significant bloodstream infections by B. clausii were reported (12). 
Two patients had stage IV lung cancer and the third one presented with 
septic shock due to ischemic colitis. As in these cases, our patient also had 
a fever and an increased count of white blood cells. While these patients 
died from other causes not related to B. clausii bacteremia, our patient 
survived throughout the hospital stance after adequate treatment of upper 
gastrointestinal bleeding and timely antimicrobial therapy. A limitation in our 
case report is the absence of antimicrobial susceptibility testing on B. clausii. 
Figure 2. Gram stain, blood culture, and MALDI-TOF results. Left: Blood culture, 
Gram stain, 100X. Right: Gram-positive rod colonies that grew on blood culture 
in solid medium, Agar Columbia (BioMérieux brand). MALDITOF result: Type 
of sample: blood culture. Identified microorganism: Bacillus clausii. This is a 
sensitive and high-precision technique for the identification of microorganisms 
through mass spectrometry analysis. Methods sequencing the 16s subunit have 
a 98% concordance for microorganism identification (Score: 2.4, highly reliable 
identification at genera and species levels)
18
García JP, Hoyos JA, Alzate JA, Cristancho E Biomédica 2021;41(Supl.2):13-20
Conversely, the isolate from one of the reported patients was penicillin-, 
clindamycin-, and tetracycline-resistant. 
Princess, et al. published a case report of bacteremia in an 
immunocompetent adult with acute diarrhea under broad-spectrum antibiotics 
prescribed to treat K. pneumoniae respiratory and surgical wound infection in 
a patient that had evacuating craniectomy after cerebral vein thrombosis and 
intraparenchymal bleeding (13). The patient also had a fever after probiotic 
administration. B. claussi was initially isolated in blood cultures as a Gram-
positive rod and identified through a MALDI-TOF assay, as was our case. 
We treated our patient with ampicillin plus gentamicin while Princess, et al. 
prescribed teicoplanin; our patient’s isolate was penicillin-resistant only (MIC: 
32 µg/ml) but, besides vancomycin and ciprofloxacin, no other antibiotics 
were tested given there were no interpretative guidelines. Another limitation 
of our study was that no control blood culture was done to assess the 
microbiological response to treatment.
Joshi, et al. reported the case of a pediatric patient with congenital heart 
disease and recurrent lower respiratory tract infections that received B. clausii 
probiotic to treat acute diarrhea (14) and was treated with IV vancomycin. The 
isolate from three blood culture samples was identified through MALDI-TOF. 
The strain was not associated with penicillin resistance but it is noteworthy 
that B. clausii bacteremia recurred although there was no repeated probiotic 
dose and the agent persisted in the blood culture despite appropriate 
vancomycin IV therapy. 
The main conclusion from this case series is the importance of being 
cautious when using probiotics, especially if there is a risk of a fatal outcome. 
Our case report adds to a previous one of B. clausii bacteremia with no 
underlying immunocompromising conditions such as active cancer or severe 
malnourishment. Even though there is no formal description of risk factors 
to develop infections by this probiotic, we can conclude that they may occur 
irrespective of the patient’s immune status. In table 3 we summarize the profile 
of the patients reported highlighting those characteristics that may behave 
as risk factors and encouraging awareness among attending physicians. 
It has yet to be determined if bacteremia by B. clausii could be related to 
worse outcomes as there are now two out of six patients who succumbed to 
conditions apparently not related to probiotic administration. The conditions 
related to an increased risk of bacteremia due to other types of probiotics 
(e.g., Lactobacillus) are older age, congenital immune deficiencies, treatment 
with antitumoral chemotherapy or ionizing radiation, extensive gastrointestinal 
ulcers, treatments with broad-spectrum antibiotics, and diabetes (15).
Table 3. Profile of patients documented with bacteremia due to Bacillus clausii administration
Authors Year of publication Age Patients’ profile Treatment Antimicrobial susceptibility
Gargar JD, et al. 2019 ND Stage IV lung cancer and pneumonia ND One case reported 
resistance to clindamycin, 
penicillin, and tetracycline.
Gargar JD, et al. 2019 ND Stage IV lung cancer and pneumonia ND
Gargar JD, et al. 2019 ND Septic shock from ischemic colitis ND
Hubiche T, et al. 2019 5 
months
Congenital heart disease, malnourishment, 
recurrent respiratory tract infections, 
repeated hospital/ICU admissions, and 
broad-spectrum antibiotics
Vancomycin Susceptibility to vancomycin 
and penicillin (E-test)
Princess, et al. 2020 Middle 
aged
Type 2 diabetes, decompressive craniotomy, 
and broad-spectrum antibiotics
Teicoplanin Susceptibility to ciprofloxacin 
and vancomycin. Resistance 
to penicillin (E-test)
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Bacillus clausii safety profile has been confirmed in randomized control 
trials for efficient treatment of acute diarrhea related to viral infection, 
Clostridioides difficile infection, and antibiotic-associated diarrhea (16). 
Notwithstanding the published recommendations, the risks of Bacillus 
probiotics include the production of enteric toxins and toxicity for normal 
cells (17). Physicians are more aware of probiotics’ benefits than of their 
risks, and, therefore, further research and case reporting are necessary 
to identify their potential harm in certain clinical contexts. We observed 
that Enterogermina™ was not efficient to treat our patient’s diarrhea by 
enteropathogenic and enteroaggregative E. coli as diarrhea persisted for 11 
days after its administration. Enterogermina™ (Bacillus clausii) administration 
in patients with recent upper gastrointestinal bleeding, acute diarrhea, and 
the use of proton pump inhibitors, which can diminish stomach pH and favor 
bacterial colonization, may lead to bacteremia through direct invasion or gut 
translocation. Therefore, B. claussi should be considered as a possible agent 
in the presence of systemic signs of infection, metabolic compromise, and 
hemodynamic instability when no other pathogens are identified to explain the 
clinical course. In such cases, the treatment should be aimed at fighting this 
Gram-positive rod with antibiotics other than clindamycin, erythromycin, and 
chloramphenicol, as B. clausii has intrinsic resistance against them (4).
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